TABLE 1.

Patient-reported outcome scale scores at baseline

		Fezolinetant
Parameters	Placebo (n = 43)	15 mg BID (n = 45)	30 mg BID (n = 43)	60 mg BID (n = 45)	90 mg BID (n = 44)	30 mg QD (n = 43)	60 mg QD (n = 45)	120 mg QD (n = 44)
MENQoL, n	43	45	43	45	42	42	44	44
Overall score	4.3 (1.6)	4.1 (1.3)	4.0 (1.3)	4.1 (1.5)	4.1 (1.3)	4.4 (1.5)	4.2 (1.5)	4.1 (1.3)
HFRDIS, n	43	45	43	45	42	42	44	44
Overall mean score	6.0 (2.3)	5.4 (2.0)	5.4 (2.1)	5.6 (2.3)	5.1 (2.3)	6.0 (2.1)	5.3 (2.3)	5.7 (2.3)
GCS, n	43	45	43	44	42	43	44	44
Overall sum	21.7 (10.3)	19.6 (8.2)	17.6 (10.1)	19.8 (12.0)	17.8 (10.3)	20.5 (9.1)	19.3 (9.3)	19.4 (10.4)

Data are means (standard deviations).

GCS, Greene climacteric scale; HFRDIS, hot flash related daily interference scale; MENQoL, menopause-specific quality of life.